- Teladoc Health press release (NYSE:TDOC): Q2 GAAP EPS of -$0.19 beats by $0.07.
- Revenue of $631.9M (-1.6% Y/Y) beats by $9.1M.
- 3Q25 revenue consensus of $628.49M, EPS consensus of -$0.24; FY25 revenue consensus of $2.52B, EPS consensus of -$1.16
| For the third quarter of 2025, we expect: | |
| 3Q 2025 Outlook Range | |
| Revenue | $614 – $636 million |
| Adjusted EBITDA | $56 – $70 million |
| Net loss per share | ($0.35) – ($0.20) |
| U.S. Integrated Care Members (2) | 101.5 – 102.5 million |
| For the full year of 2025, we expect: | |
| Full Year 2025 Outlook Range | |
| Revenue | $2,501 – $2,548 million |
| Adjusted EBITDA | $263 – $294 million |
| Net loss per share | ($1.35) – ($1.00) |
| Free Cash Flow | $170 – $200 million |
| U.S. Integrated Care Members (2) | 101 – 103 million |
More on Teladoc Health
- Teladoc Health: A Beaten-Down Bargain Worth A Second Look (Upgrade)
- Teladoc: Attractively Valued, Potential For Revenue Growth And Multiple Expansion
- Teladoc Health, Inc. (TDOC) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
- Teladoc Health likely to post a Q2 loss and year-over-year decline in revenue
- Biggest stock movers Tuesday: CCL, TDOC, CHWY, and more